Credit: WCM
Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.
The results, which were published Dec. 24 in the
Share this article
Share this article
TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company s COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with KEYTRUDA
® (pembrolizumab) and chemotherapy in patients with second-line stage IV pancreatic ductal adenocarcinoma (PDAC).
A total of 43 patients initially diagnosed with unresectable stage IV metastatic PDAC, who had progressed following first-line gemcitabine-based therapy, were enrolled in the triple combination arm. Patients received motixafortide monotherapy priming treatment for five days, followed by combination cycles of motixafortide, KEYTRUDA
Studies offer tips on lessening spaceflight-related risk
December 4, 2020
Space travel, illnesses like COVID-19 and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and other investigators.
The discoveries, including new maps of the abundance of mutations and immune changes found in blood cells during spaceflight, may lead to new ways to protect space travelers. They may also provide insights on caring for Earth-bound patients with illnesses that trigger similar physiological responses.
Christopher Mason, an associate professor of physiology and biophysics at Weill Cornell Medicine, led multiple studies by teams of investigators spanning four of the largest space agencies in the world – NASA; the Japan Aerospace Exploration Agency (JAXA); the European Space Agency (ESA); and Russia’s ROSCOSMOS – as well as academic institutions and industry groups.
Scientists discover a key genetic driver of lymphomas medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.